Synapse

← Future HIV Therapy

Papers in Future HIV Therapy

Page 1 · newest first

  1. Proposed Guidelines for the Prevention of Mother-To-Child Transmission of HIV in Middle-Income Countries: The Thai Red Cross Pmtct GuidelinesFuture HIV Therapy · 2008
  2. Self-Reported Low Physical Function is Associated with Diabetes Mellitus and Insulin Resistance in HIV-Positive and HIV-Negative MenFuture HIV Therapy · 2008
  3. Etravirine: A Second-Generation Nnrti for Treatment-Experienced Adults with Resistant HIV-1 InfectionFuture HIV Therapy · 2008
  4. Drug Resistance Differences Among HIV Types and Subtypes: A Growing ProblemFuture HIV Therapy · 2008
  5. Rnai as a Potential New Therapy for HIV InfectionFuture HIV Therapy · 2008
  6. The White and the Three-Letter Plague: Integration of TB and HIV Care in Sub-Saharan AfricaFuture HIV Therapy · 2008
  7. Update on the Development of HIV Entry InhibitorsFuture HIV Therapy · 2008
  8. Prophylaxis and Treatment of Malaria in HIV-Infected PopulationsFuture HIV Therapy · 2008
  9. Clinical Significance of HIV-Associated Bone Loss: When and How to InterveneFuture HIV Therapy · 2008
  10. Of Mice and Monkeys: New Advances in Animal Models to Study HIV-1 Therapy and ProphylaxisFuture HIV Therapy · 2008
  11. Transcriptional Gene Silencing as a Genetic Therapy for HIV-1Future HIV Therapy · 2008
  12. Cytotoxic T Lymphocyte Responses in HIV-1-Infected Long-Term Nonprogressors: Lessons for Vaccine DesignFuture HIV Therapy · 2008
  13. Oxidative Stress and HIV Infection: Target Pathways for Novel Therapies?Future HIV Therapy · 2008
  14. Different Disease Progression Rate According to HIV-1 SubtypeFuture HIV Therapy · 2008
  15. Modeling HIV Infection Dynamics: The Role of Recombination in the Development of Drug ResistanceFuture HIV Therapy · 2008
  16. Developing Neuroprotective Strategies for Treatment of HIV-Associated Neurocognitive DysfunctionFuture HIV Therapy · 2008
  17. Immune Restoration Disease Complicating Antiretroviral Therapy in Patients with HIV Infection: Implications and SolutionsFuture HIV Therapy · 2008
  18. Socs1: A Host Factor Required for HIV-1 Gag TraffickingFuture HIV Therapy · 2008
  19. When Should Antiretroviral Therapy Be Started for HIV-Infected Infants in Resource-Limited Settings?Future HIV Therapy · 2008
  20. Induction–Maintenance Therapy for HIV-1 InfectionFuture HIV Therapy · 2008
  21. Identifying Membrane Protein Surface Markers of HIV-1 InfectionFuture HIV Therapy · 2008
  22. Function and Polymorphisms of Anti-Hiv Host Factors: Evidence from Exposed Uninfected IndividualsFuture HIV Therapy · 2008
  23. Maraviroc: A Ccr5 AntagonistFuture HIV Therapy · 2008
  24. Darunavir: A New HIV-1 Protease Inhibitor for the Treatment of HIV InfectionFuture HIV Therapy · 2008
  25. Cardiovascular Risk and Choice of HIV Drug RegimenFuture HIV Therapy · 2007
  26. For-Profit Policies and Equitable Access to Antiretroviral Drugs in Resource-Limited CountriesFuture HIV Therapy · 2007
  27. Cytokine Findings in the CSF of HIV-Positive PatientsFuture HIV Therapy · 2007
  28. Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of NnrtisFuture HIV Therapy · 2007
  29. Role of the HIV-1 Regulatory Protein NefFuture HIV Therapy · 2007
  30. Implications from the SIV Model in Understanding HIV NeutralizationFuture HIV Therapy · 2007
  31. Concurrent Drug Therapy for Tuberculosis and HIV Infection in Resource-Limited Settings: Present Status and Future ProspectsFuture HIV Therapy · 2007
  32. Host Genetic Variation and Susceptibility to Primate LentivirusesFuture HIV Therapy · 2007
  33. Host Cell Factors and HIV-1 IntegrationFuture HIV Therapy · 2007
  34. HIV-1 Gag TraffickingFuture HIV Therapy · 2007
  35. Targeting Protein–Protein Interactions for HIV TherapeuticsFuture HIV Therapy · 2007
  36. Strategies for the Optimal Sequencing of Antiretroviral Drugs Toward Overcoming and Preventing Drug ResistanceFuture HIV Therapy · 2007
  37. Non-Neutralizing Antibodies and Vaccine-Induced Protection Against HIVFuture HIV Therapy · 2007
  38. Biologically Active Coumarins as Inhibitors of HIV-1Future HIV Therapy · 2007
  39. Clinical Impact of HIV-1 Subtype: Are There Important Differences?Future HIV Therapy · 2007
  40. Busting a Gut Understanding HIV Pathogenesis in Lymphoid TissueFuture HIV Therapy · 2007
  41. Molecular Mechanisms of HIV-1 Resistance to Nucleoside and Nucleotide Reverse Transcriptase InhibitorsFuture HIV Therapy · 2007
  42. Important Considerations Regarding Antiretroviral Therapy in HIV-Positive WomenFuture HIV Therapy · 2007
  43. Microbicides in HIV PreventionFuture HIV Therapy · 2007
  44. Combined Use of Cytokines, Hormones and Therapeutic Vaccines During Effective Antiretroviral TherapyFuture HIV Therapy · 2007
  45. The Bull‘S-Eye for HIV Vaccine Development DefinedFuture HIV Therapy · 2007
  46. Treating Pregnant Women with Highly Active Antiretroviral TherapyFuture HIV Therapy · 2007
  47. Metabolic Complications of HIV Infection and Its Therapy in ChildrenFuture HIV Therapy · 2007
  48. Strategies for Targeting HIV-1 Envelope Glycoprotein Gp120 in the Development of New AntiviralsFuture HIV Therapy · 2007
  49. Nevirapine Prophylaxis for the Prevention of Perinatal HIV and the Impact of Resistance Mutations on Subsequent TherapyFuture HIV Therapy · 2007
  50. Development of Resistance After Administration of Single-Dose Nevirapine to Prevent Mother-To-Child Transmission of HIVFuture HIV Therapy · 2007